Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

Simona Sica, F. Lo-Coco, G. Avvisati, M. Vignetti, C. Thiede, S. M. Orlando, S. Iacobelli, F. Ferrara, P. Fazi, L. Cicconi, E. Di Bona, G. Specchia, M. Divona, A. Levis, W. Fiedler, E. Cerqui, M. Breccia, G. Fioritoni, H. R. Salih, M. CazzolaL. Melillo, A. M. Carella, C. H. Brandts, E. Morra, M. Von Lilienfeld-Toal, B. Hertenstein, M. Wattad, M. Lübbert, M. Hänel, N. Schmitz, H. Link, M. G. Kropp, A. Rambaldi, G. La Nasa, M. Luppi, F. Ciceri, O. Finizio, A. Venditti, F. Fabbiano, K. Döhner, M. Sauer, A. Ganser, S. Amadori, F. Mandelli, H. Döhner, G. Ehninger, R. F. Schlenk, U. Platzbecker

Research output: Contribution to journalArticle

819 Citations (Scopus)


All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity.
Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalNew England Journal of Medicine
Publication statusPublished - 2013


  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Arsenicals
  • Consolidation Chemotherapy
  • Disease-Free Survival
  • Female
  • Humans
  • Induction Chemotherapy
  • Leukemia, Promyelocytic, Acute
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Neutropenia
  • Oxides
  • Thrombocytopenia
  • Tretinoin
  • Young Adult


Dive into the research topics of 'Retinoic acid and arsenic trioxide for acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this